Comparison
Tesamorelin vs Sermorelin: What the Research Distinguishes
Both are GHRH analogues. The difference is structural — chain length and a stabilizing modification — and the literature supports a structural comparison, not a head-to-head efficacy verdict.
The short version
Tesamorelin vs sermorelin comes down to two design choices. Both are lab-made versions of GHRH (the brain's own "make growth hormone" signal), and both nudge the pituitary gland to release the body's own growth hormone. The differences: tesamorelin copies the full natural hormone (all 44 amino acids) and adds a chemical cap that stops it from being broken down quickly; sermorelin uses a shorter fragment (the first 29 amino acids) and has no such cap. One has been through large FDA-approval trials for a specific HIV condition; the other has a different and older regulatory history. This page compares the chemistry, not which one "wins" — no trial has ever put them head-to-head.
The structural difference: full-length and stabilized vs truncated
Tesamorelin is a full-length GHRH(1-44) analogue — it reproduces the complete 44-amino-acid sequence of human growth hormone-releasing hormone and adds a trans-3-hexenoic acid group on the N-terminus. Sermorelin is GHRH(1-29): a truncated fragment comprising only the first 29 amino acids, which is the minimum sequence retaining GH-releasing activity. The two molecules therefore start from different lengths of the same parent hormone.
The stabilizing modification is the second axis of difference. Tesamorelin's N-terminal trans-3-hexenoic acid group confers resistance to DPP-IV — the protease that rapidly inactivates native GHRH. Sermorelin carries no such modification. That is the chemistry the comparison rests on: tesamorelin is built both longer and tougher.
It is worth stating the comparison precisely rather than loosely. Three axes separate the two: chain length (44 amino acids versus 29), the presence or absence of an N-terminal stabilizing group (present in tesamorelin, absent in sermorelin), and the resulting susceptibility to DPP-IV (resistant versus not). Tesamorelin carries the CAS identifier 218949-48-5 and a molecular weight of 5,135.9 Da, reflecting both the longer sequence and the added fatty-acid group. None of these structural facts, on their own, predicts a clinical outcome — they describe how each molecule is built, which is the honest scope of a structural comparison.
Why DPP-IV resistance matters mechanically
Native GHRH is cleaved by DPP-IV within minutes, which limits how long any unmodified GHRH-based molecule can signal. Tesamorelin's N-terminal modification blocks that cleavage, extending its biological activity relative to native GHRH. Mechanically, this means a stabilized GHRH analogue can keep engaging the GHRH receptor longer than the unprotected sequence would — and in healthy men, tesamorelin demonstrably augmented endogenous pulsatile GH release over a two-week course [6].
This is a mechanistic and pharmacologic distinction drawn from the structure, not a claim that one analogue outperforms the other in a clinical endpoint. No randomized trial has compared tesamorelin and sermorelin head-to-head, so any efficacy ranking would be an inference beyond the published evidence. What the literature does support is the structural reading: full-length and DPP-IV-resistant on one side, truncated and unmodified on the other.
Different evidence bases and regulatory frames
The two compounds also differ in what has been studied and approved. Tesamorelin carries an unusually deep human evidence base for its class — two pivotal Phase 3 RCTs in HIV-associated lipodystrophy [1][2], an earlier dose-ranging trial [7], a JAMA liver-fat trial [3], dedicated PK and PK/PD analyses [8][9], and a 2026 meta-analysis [12] — and is FDA-approved (NDA 022505, 2010) solely for reducing excess abdominal fat in HIV patients with lipodystrophy [5]. Sermorelin has a separate, older regulatory and research history not covered by this digest.
For tesamorelin, the approval scope is the load-bearing fact: approved for HIV-associated lipodystrophy, off-label for everything else [5]. A structural similarity to another GHRH analogue does not transfer any approval or efficacy claim between them. Both raise the body's own GH by the same broad mechanism; the differences this page documents are chain length, stabilization, and the evidence each has accumulated. Notably, anti-doping science treats them as a family: a 2026 urine assay was validated to screen sermorelin, tesamorelin, and related GHRH analogues together [13].